Our team is developing precision medicines for oncology and other therapeutic areas. We are exclusively focused on drugging transcription factors to fully unlock the therapeutic potential of this previously elusive target class.
By leveraging our integrated discovery platform of capabilities, we identify novel validated ligands to the undrugged proteome.
Our lead program, FX-909, is a first-in-class orally available small molecule inhibitor of PPARG, a master regulator of the luminal lineage, that is initially being developed for locally advanced or metastatic urothelial cancer.
FX-909 has achieved clinical proof-of-concept in a Phase 1A study as a monotherapy and is actively dosing patients in a Phase 1B.
